Gotham Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.3M | Buy |
91,626
+30,426
| +50% | +$5.32M | 0.05% | 510 |
|
|
2025
Q4 | $10.4M | Buy |
61,200
+10,008
| +20% | +$1.53M | 0.04% | 624 |
|
|
2025
Q3 | $6.75M | Sell |
51,192
-17,280
| -25% | -$2.07M | 0.03% | 698 |
|
|
2025
Q2 | $7.27M | Buy |
68,472
+18,077
| +36% | +$1.96M | 0.04% | 554 |
|
|
2025
Q1 | $6.26M | Buy |
50,395
+35,304
| +234% | +$4.61M | 0.05% | 481 |
|
|
2024
Q4 | $1.86M | Sell |
15,091
-5,942
| -28% | -$700K | 0.02% | 744 |
|
|
2024
Q3 | $2.34M | Buy |
21,033
+15,033
| +251% | +$1.65M | 0.02% | 684 |
|
|
2024
Q2 | $640K | Buy |
6,000
+3,140
| +110% | +$345K | 0.01% | 1017 |
|
|
2024
Q1 | $344K | Sell |
2,860
-963
| -25% | -$118K | 0.01% | 1156 |
|
|
2023
Q4 | $470K | Sell |
3,823
-20,149
| -84% | -$2.51M | 0.01% | 1005 |
|
|
2023
Q3 | $3.1M | Sell |
23,972
-5,220
| -18% | -$696K | 0.06% | 428 |
|
|
2023
Q2 | $3.62M | Buy |
29,192
+1,756
| +6% | +$236K | 0.08% | 352 |
|
|
2023
Q1 | $4.01M | Buy |
27,436
+3,492
| +15% | +$517K | 0.1% | 267 |
|
|
2022
Q4 | $3.81M | Buy |
23,944
+11,998
| +100% | +$1.76M | 0.11% | 236 |
|
|
2022
Q3 | $1.59M | Buy |
+11,946
| New | +$1.82M | 0.05% | 479 |
|
|
2021
Q3 | – | Sell |
-1,614
| Closed | -$287K | – | 1071 |
|
|
2021
Q2 | $287K | Sell |
1,614
-10,350
| -87% | -$1.79M | 0.01% | 862 |
|
|
2021
Q1 | $1.97M | Buy |
11,964
+10,163
| +564% | +$1.67M | 0.09% | 299 |
|
|
2020
Q4 | $297K | Sell |
1,801
-241
| -12% | -$35.9K | 0.01% | 838 |
|
|
2020
Q3 | $291K | Sell |
2,042
-19,521
| -91% | -$2.42M | 0.01% | 844 |
|
|
2020
Q2 | $2.38M | Buy |
+21,563
| New | +$2.38M | 0.07% | 346 |
|
|
2020
Q1 | – | Sell |
-4,315
| Closed | -$644K | – | 1139 |
|
|
2019
Q4 | $644K | Sell |
4,315
-8,445
| -66% | -$1.15M | 0.01% | 727 |
|
|
2019
Q3 | $1.64M | Sell |
12,760
-10,864
| -46% | -$1.46M | 0.03% | 485 |
|
|
2019
Q2 | $3.37M | Buy |
23,624
+2,126
| +10% | +$286K | 0.05% | 400 |
|
|
2019
Q1 | $3.07M | Sell |
21,498
-18,055
| -46% | -$2.35M | 0.05% | 426 |
|
|
2018
Q4 | $4.9M | Sell |
39,553
-1,771
| -4% | -$263K | 0.08% | 338 |
|
|
2018
Q3 | $6.95M | Buy |
+41,324
| New | +$7.11M | 0.1% | 288 |
|
|
2018
Q1 | – | Sell |
-17,170
| Closed | -$2.31M | – | 1008 |
|
|
2017
Q4 | $2.31M | Sell |
17,170
-16,887
| -50% | -$2.34M | 0.03% | 476 |
|
|
2017
Q3 | $4.98M | Buy |
34,057
+3,749
| +12% | +$567K | 0.07% | 360 |
|
|
2017
Q2 | $4.71M | Buy |
30,308
+17,692
| +140% | +$2.71M | 0.07% | 372 |
|
|
2017
Q1 | $1.83M | Sell |
12,616
-68,801
| -85% | -$8.96M | 0.02% | 562 |
|
|
2016
Q4 | $8.88M | Sell |
81,417
-71,834
| -47% | -$8M | 0.11% | 276 |
|
|
2016
Q3 | $18.6M | Buy |
153,251
+47,847
| +45% | +$6.45M | 0.24% | 138 |
|
|
2016
Q2 | $14.9M | Sell |
105,404
-92,215
| -47% | -$13.6M | 0.18% | 186 |
|
|
2016
Q1 | $25.8M | Buy |
197,619
+12,658
| +7% | +$1.58M | 0.29% | 97 |
|
|
2015
Q4 | $26M | Buy |
184,961
+159,289
| +620% | +$22.1M | 0.28% | 117 |
|
|
2015
Q3 | $3.41M | Buy |
25,672
+22,107
| +620% | +$3.81M | 0.03% | 469 |
|
|
2015
Q2 | $628K | Sell |
3,565
-7,309
| -67% | -$1.31M | 0.01% | 702 |
|
|
2015
Q1 | $1.88M | Buy |
+10,874
| New | +$1.87M | 0.01% | 524 |
|
|
2014
Q2 | – | Sell |
-7,367
| Closed | -$1.02M | – | 1043 |
|
|
2014
Q1 | $1.02M | Buy |
+7,367
| New | +$1.11M | 0.02% | 651 |
|
Other funds holding JAZZ
VPM
VCM
EC
Gotham Asset Management's JAZZ Position: Q1 2026 in Review
Gotham Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 50% in Q1 2026, buying an estimated $5.32M and bringing the position to 91,626 shares worth $17.3M. The position accounts for 0.05% of the portfolio, ranked #510.
Gotham Asset Management first reported a position in JAZZ in Q1 2014 and has held it in 39 quarters since. The position peaked at $26M in Q4 2015. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Gotham Asset Management held 91,626 shares of Jazz Pharmaceuticals worth $17.3M as of Q1 2026.
- Gotham Asset Management bought 30,426 Jazz Pharmaceuticals shares in Q1 2026, an estimated $5.32M.
- Jazz Pharmaceuticals made up 0.05% of Gotham Asset Management's portfolio in Q1 2026, its #510 holding.
- Gotham Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and has held it in 39 quarters since.
- Gotham Asset Management's Jazz Pharmaceuticals position peaked at $26M in Q4 2015.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.